AstraZeneca: sells commercial rights to hypertension drug
(CercleFinance.com) - AstraZeneca a annoncé vendredi la signature d'un accord visant à céder à l'allemand Cheplapharm les droits de commercialisation dans 70 pays d'un traitement de l'hypertension artérielle.
On Friday AstraZeneca announced that it has signed an agreement to sell the rights to market a treatment for high blood pressure in 70 countries, to Germany's Cheplapharm.
This drug, Atacand, as well as its reinforced version Atacand Plus, will be sold for a total of 400 million dollars, of which 250 million dollars will be paid on the deal's completion, AstraZeneca said in a statement.
The biopharmaceutical group points out that it is seeking to get rid of its "mature" drugs in order to concentrate on areas considered more promising, such as oncology and immunology.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
On Friday AstraZeneca announced that it has signed an agreement to sell the rights to market a treatment for high blood pressure in 70 countries, to Germany's Cheplapharm.
This drug, Atacand, as well as its reinforced version Atacand Plus, will be sold for a total of 400 million dollars, of which 250 million dollars will be paid on the deal's completion, AstraZeneca said in a statement.
The biopharmaceutical group points out that it is seeking to get rid of its "mature" drugs in order to concentrate on areas considered more promising, such as oncology and immunology.
Copyright (c) 2020 CercleFinance.com. All rights reserved.